Clinical Trials
8 trialsNCT07000110 2026-05-20
SIMA
AstraZeneca
Recruiting
NCT06790420 2026-05-15
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
Pfizer
Completed
NCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02922543 2022-06-14
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
Completed
NCT03087370 2018-12-07
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
X4 Pharmaceuticals
Withdrawn
NCT01062074 2017-04-17
GARDASIL Reexamination Study (V501-059)
Merck Sharp & Dohme LLC
Completed